1 |
Hayes DF, Zurawski NR, Kufe DW. Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clinic Oncol 1986;4:1542-50
DOI
|
2 |
ASCO Special Article. Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology. J Clin Oncol 1997;15:2149-56
|
3 |
Linsley PS, Ochs V, Laska S, Horn D, Ring DB, Frankel AE, et al. Elevated levels of a high molecular weight antigen detected by antibody W1 in sera from breast cancer patients. Cancer Res 1986;46:5444-50
PUBMED
|
4 |
Kim H, Le YH. CA 15-3 in patients with primary and recurrent breast cancer. J Korean Surg Soc 1995;50:36-41
|
5 |
Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localized breast cancer: a prospective study. Eur J Cancer 2002;38:1189-93
DOI
ScienceOn
|
6 |
Safi F, Kohler I, Rottinger E, Suhr P, Beger HG. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989;4:207-214
PUBMED
|
7 |
Krengli M, Pastore G, Maffei S. The importance of the follow-up in patients operated on for breast cancer. A retrospective analysis of 2482 cases. Minerva Med 1993;84:409-15
|
8 |
ASCO Special Article. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78
|
9 |
Moon SD, Jung SS, Kim IC, Lee DS. Comparison of CA 15-3 with CEA as tumor marker of breast cander. J of Korean Cancer Assoc 1992;24:829-33
|
10 |
Wojtacki J, Kruszewski WJ, Sliwinska M, Kruszewska E, Hajdukiewicz W, Sliwinski W, et al. Elevation of serum CA 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases. Przegl Lek 2001;58:498-503
PUBMED
|
11 |
O'Rourke TJ: Tumor markers. In; Calabresi P, Schein PS, et al. Medical oncology: basic principles and clinical management of cancer, 2nd ed., pp 163-172, New York, Mcgraw-Hill, inc., 1993
|
12 |
Thompson CH, Jones SL, Whitehead RH, McKenzie IF. A human breast tissue-associated antigen detected by a monoclonal antibody. J Natl Cancer Inst 1983;70:409-19
PUBMED
|
13 |
Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, et al. Prognostic role of serum CA 15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 2002;38:1181-8
|
14 |
Ministry of Health and Welfare, Republic of Korea Annual Report of Cancer Registry Programme in the Republic of Korea. (2000.1.1-2000.12.31), 2002
|
15 |
Jung JH, Park HY, Lee YH. Clinical value of CEA, CA 15-3 and TPS in breast cancer. J Korean Breast Cancer Soc 2001;4:136-43
DOI
|
16 |
Kim S-H. Chemotherapy of breast cancer. Kor J Med 2000;58:497-509
|
17 |
ASCO Special Article. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77
DOI
|
18 |
Kim HK, Heo DS, BangY-J, Kim NK. Pattern of recurrence of breast cancer in Korean female patients. J of Korean Cancer Assoc 1999;31:509-16
|
19 |
Buffaz P-D, Gauchez A-S, Caravel J-P, Vuillez J-P, Cura C, Agnius-Delord C, et al. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers? Eur J Nucl Med 1999;26:8-11
|
20 |
Cheung KL. Editorial comment on 'Serum markers in breast cancer management' Eur J Cancer 2002;38:1165-6
|
21 |
Fisher B, Slack N, Katrych D, Wolmark N: Ten years follow-up results of patients with carcinoma of the breast in a cooperative trial evaluation surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975;140:528-34
PUBMED
|